Sumitomo Chemical Company (4005) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
1 Jul, 2026Executive summary
Core operating income for H1 FY2024 achieved a V-shaped recovery, up over ¥120 billion year-on-year, led by IT-related Chemicals and Pharmaceuticals; net loss of ¥6.5 billion was recorded, mainly due to foreign exchange losses and Petro Rabigh debt forgiveness.
Full-year FY2024 forecast: core operating income of ¥100 billion and net income of ¥25 billion, both revised upward despite one-off losses.
Accelerated business portfolio upgrades, with a raised cash generation target of ¥700 billion and expected reduction of interest-bearing liabilities by ¥300 billion.
Structural reforms underway, including cost reductions and sales expansion in Pharma, operational optimization in domestic petrochemicals, and a new 4-segment organization launched in October 2024.
Interim dividend of ¥3 per share declared, with annual DPS maintained at ¥9.
Financial highlights
H1 FY2024 sales revenue: ¥1,241.4 billion, up ¥54.5 billion year-on-year; core operating income: ¥29.5 billion; net loss: ¥6.5 billion.
Core operating income increased by ¥126.1 billion year-on-year, marking a significant recovery.
All segments improved year-on-year; IT-related Chemicals income rose ¥19.7 billion to a record high of ¥37.5 billion.
Health & Crop Sciences saw profit growth due to methionine market recovery, increased crop protection shipments, and yen depreciation.
Full-year forecast: sales revenue ¥2,600 billion, core operating income ¥100 billion, net income ¥25 billion (including a ¥46 billion one-off loss).
Outlook and guidance
FY2024 core operating income forecast remains at ¥100 billion, with segment-level ups and downs; net income forecast at ¥25 billion.
Essential Chemicals expected to decrease by ¥24 billion due to Petro Rabigh's downturn; IT-related Chemicals forecast to increase by ¥10 billion.
FY2025 target: maintain core operating income at ¥100 billion, focusing on organic growth and improved Rabigh performance.
New medium-term management plan to be formulated under a reorganized structure starting October.
Dividend policy maintained at ¥9 per share for FY2024, with a future aim of ¥24/share or more.
Latest events from Sumitomo Chemical Company
- Core operating income and net income rose sharply, with FY2026 set for further growth.4005
Q4 202618 May 2026 - Profits soared on divestitures and pharma gains, but Q4 losses and risks persist.4005
Q3 20263 Feb 2026 - Q3 FY2024 delivered a strong profit rebound and segment growth, with guidance maintained.4005
Q3 20259 Jan 2026 - V-shaped recovery and growth driven by Agro, ICT, and reforms, targeting 200bn yen by FY2027.4005
Status Update16 Dec 2025 - FY2024 saw a sharp profit rebound and improved cash flow, with higher dividends ahead.4005
Q4 202520 Nov 2025 - Core operating income rose sharply despite lower sales and FX losses; outlook is positive.4005
Q1 202616 Nov 2025 - Profit rebounded sharply on pharma gains and asset sales, with a raised full-year outlook.4005
Q2 20264 Nov 2025 - Growth strategy leverages tech strengths, reforms, and portfolio upgrades for resilience and efficiency.4005
Status Update25 Sep 2025 - Profitability returned, led by IT-related Chemicals and improved segment results.4005
Q1 202513 Jun 2025